This list is an analysis based on recent market events. It's not an investment recommendation.
About
Tetra Bio-Pharma Inc., a biopharmaceutical company, engages in the discovery and development of cannabinoid-derived drugs for inflammation, pain, ophthalmology, and oncology. The company develops PLENITUDE to treat cancer-related pain in advanced cancer patients; REBORN for the treatment of breakthrough cancer pain; Reduvo for chemotherapy-induced nausea and vomiting; ARDS-003 for the treatment of sepsis and prevention of acute respiratory distress syndrome; and SERENITY to treat cancer cachexia. It also develops PPP003 for painful dry eye and uveitis pain; and HCC011 for hepatocellular carcinoma. Tetra Bio-Pharma Inc. has an agreement with Cellvera Global Holdings LLC for the co-development of ARDS-003 as a combination product with Qifenda 400MG (Favipiravir), a commercial-stage broad-spectrum antiviral drug. The company is headquartered in Orléans, Canada.
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Tetra Bio-Pharma stocks are traded under the ticker JAM1.STU.
What is Tetra Bio-Pharma revenue for the last year?▼
Tetra Bio-Pharma revenue for the last year amounts to 0 EUR.
What is Tetra Bio-Pharma net income for the last year?▼
JAM1.STU net income for the last year is -35.5M EUR.
How many employees does Tetra Bio-Pharma have?▼
As of July 16, 2026, the company has 33 employees.
In which sector is Tetra Bio-Pharma located?▼
Tetra Bio-Pharma operates in the Health & Wellness sector.
When did Tetra Bio-Pharma complete a stock split?▼
Tetra Bio-Pharma has not had any recent stock splits.
Where is Tetra Bio-Pharma headquartered?▼
Tetra Bio-Pharma is headquartered in Orléans, Canada.